Ondine Biomedical (AIM:OBI) has had two abstracts accepted for poster presentation at the World Congress on Infectious Diseases in Barcelona (25-27 June), bringing long‑term clinical and economic data that the company says demonstrate durable benefits from its Steriwave nasal photodisinfection system.
One poster, Breaking the Mupirocin Paradox, reports a 66% reduction in surgical site infections (SSIs) in complex spine surgery over eight years and finds no signals of antimicrobial resistance. The second, The Double Whammy of Cardiac SSI Under‑Reporting, argues that short‑term SSI rates and unadjusted cost data understate the true clinical and financial burden, limiting policy and purchasing changes.
"Nasal photodisinfection has demonstrated sustained reductions in SSI rates over many years without any observed loss of efficacy," Carolyn Cross, CEO of Ondine Biomedical, said.
Ondine frames the findings as evidence for a non‑antibiotic approach that avoids resistance while delivering immediate pathogen reduction; Steriwave is CE‑marked in Europe and approved for nasal decolonisation in Canada, Australia and Mexico. Both abstracts will be available in the Poster Presentation (Virtual) category, allowing international access to the data during the congress on 25-27 June.
